A recent multipopulation pooled cumulative exposure analysis has suggested that the use of pioglitazone is not associated with an increased incidence of bladder cancer. The study used prescription, cancer and mortality data from patients with type 2 diabetes. The raw data were obtained from British Columbia, Finland, Manchester, Rotterdam, Scotland and the UK Clinical Practice Research Datalink. Data were collected on 1.01 million patients over 5.9 million person-years. There were 3,248 cases of incident bladder cancer, 117 in those exposed to pioglitazone, over a median follow-up of 4.0 to 7.4 years.